English
简体中文
Total: £ 56.28
Published Date: 2025-12-17 | Pages: 139 | Tables: 133 | Pharma & Healthcare
The global market for RDC Drugs was valued at US$ 9852 million in the year 2024 and is projected to reach a revised size of US$ 18191 million by 2031, growing at a CAGR of 9.2% during the forecast period.
RDC drugs are a novel type of therapeutic drug combining precise targeting and potent killing. Their structure is similar to antibody-drug conjugates (ADCs), but the toxic payload is replaced by a radionuclide. They mainly consist of four parts: a targeting ligand responsible for specific tumor recognition, a linker arm, a chelating agent to stabilize the bound radionuclide, and the radionuclide itself. After entering the body, the ligand guides the radionuclide to precisely accumulate at the tumor site. The radiation released during radionuclide decay destroys tumor cell DNA from within, achieving highly effective treatment. If imaging radionuclides are used, they can be used for tumor localization and diagnosis.
The RDC drug market has extremely broad prospects and is leading the rapid rise of the radiopharmaceutical industry. The core drivers of future growth lie in technological iteration and application expansion. Therapeutic radionuclides are upgrading from current β-radionuclides (such as lutetium-177) to next-generation alpha radionuclides (such as actinium-225) with stronger and more precise killing power; indications are expanding from prostate cancer and neuroendocrine tumors to more solid tumors and even non-tumor fields. With policy support and capital investment, pharmaceutical companies from various countries are vying to break through bottlenecks in the industrial chain, such as isotope supply, production and distribution. The unique advantages of integrated diagnosis and treatment will make RDC an important pillar for precision cancer treatment.
North American market for RDC Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for RDC Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for RDC Drugs in Prostate Cancer is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of RDC Drugs include Novartis, Bayer, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Johnson & Johnson, Grand Pharmaceutical Group, China Isotope & Radiation Corporation, Dongcheng Pharmaceutical, Hengrui Medicine, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for RDC Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RDC Drugs.
The RDC Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global RDC Drugs market comprehensively. Regional market sizes, concerning products by Target Ligand Types, by Application, by Medical Uses and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RDC Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Target Ligand Types, by Application, and by regions.
Market Segmentation
By Company
Novartis
Bayer
AstraZeneca
Eli Lilly
Bristol-Myers Squibb
Johnson & Johnson
Grand Pharmaceutical Group
China Isotope & Radiation Corporation
Dongcheng Pharmaceutical
Hengrui Medicine
Xiantong Pharmaceutical
Bivision
SmartNuclide
Full-Life Technologies
Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
Nuoyu Pharmaceutical
Segment by Target Ligand Types
Antibody-Drug Conjugates (ARC)
Peptide-Drug Conjugates (PRC)
Small Molecule-Drug Conjugates (SMRC)
Segment by Medical Uses
Diagnostic RDCs
Therapeutic RDCs
Segment by Therapeutic Radionuclide Properties
β-Nuclear Therapy
α-Nuclear Therapy
Segment by Application
Prostate Cancer
Neuroendocrine Tumors
Liver Cancer
Kidney Cancer
Bone Metastases
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Target Ligand Types, by Application, by Medical Uses etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RDC Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Target Ligand Types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Target Ligand Types
1.2.1 Global RDC Drugs Market Size Growth Rate by Target Ligand Types: 2020 VS 2024 VS 2031
1.2.2 Antibody-Drug Conjugates (ARC)
1.2.3 Peptide-Drug Conjugates (PRC)
1.2.4 Small Molecule-Drug Conjugates (SMRC)
1.3 Market by Medical Uses
1.3.1 Global RDC Drugs Market Size Growth Rate by Medical Uses: 2020 VS 2024 VS 2031
1.3.2 Diagnostic RDCs
1.3.3 Therapeutic RDCs
1.4 Market by Therapeutic Radionuclide Properties
1.4.1 Global RDC Drugs Market Size Growth Rate by Therapeutic Radionuclide Properties: 2020 VS 2024 VS 2031
1.4.2 β-Nuclear Therapy
1.4.3 α-Nuclear Therapy
1.5 Market by Application
1.5.1 Global RDC Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.5.2 Prostate Cancer
1.5.3 Neuroendocrine Tumors
1.5.4 Liver Cancer
1.5.5 Kidney Cancer
1.5.6 Bone Metastases
1.5.7 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global RDC Drugs Market Perspective (2020-2031)
2.2 Global RDC Drugs Growth Trends by Region
2.2.1 Global RDC Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 RDC Drugs Historic Market Size by Region (2020-2025)
2.2.3 RDC Drugs Forecasted Market Size by Region (2026-2031)
2.3 RDC Drugs Market Dynamics
2.3.1 RDC Drugs Industry Trends
2.3.2 RDC Drugs Market Drivers
2.3.3 RDC Drugs Market Challenges
2.3.4 RDC Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RDC Drugs Players by Revenue
3.1.1 Global Top RDC Drugs Players by Revenue (2020-2025)
3.1.2 Global RDC Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Top RDC Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by RDC Drugs Revenue
3.4 Global RDC Drugs Market Concentration Ratio
3.4.1 Global RDC Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RDC Drugs Revenue in 2024
3.5 Global Key Players of RDC Drugs Head office and Area Served
3.6 Global Key Players of RDC Drugs, Product and Application
3.7 Global Key Players of RDC Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 RDC Drugs Breakdown Data by Target Ligand Types
4.1 Global RDC Drugs Historic Market Size by Target Ligand Types (2020-2025)
4.2 Global RDC Drugs Forecasted Market Size by Target Ligand Types (2026-2031)
5 RDC Drugs Breakdown Data by Application
5.1 Global RDC Drugs Historic Market Size by Application (2020-2025)
5.2 Global RDC Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America RDC Drugs Market Size (2020-2031)
6.2 North America RDC Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America RDC Drugs Market Size by Country (2020-2025)
6.4 North America RDC Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RDC Drugs Market Size (2020-2031)
7.2 Europe RDC Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe RDC Drugs Market Size by Country (2020-2025)
7.4 Europe RDC Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific RDC Drugs Market Size (2020-2031)
8.2 Asia-Pacific RDC Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific RDC Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific RDC Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America RDC Drugs Market Size (2020-2031)
9.2 Latin America RDC Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America RDC Drugs Market Size by Country (2020-2025)
9.4 Latin America RDC Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RDC Drugs Market Size (2020-2031)
10.2 Middle East & Africa RDC Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa RDC Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa RDC Drugs Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis RDC Drugs Introduction
11.1.4 Novartis Revenue in RDC Drugs Business (2020-2025)
11.1.5 Novartis Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer RDC Drugs Introduction
11.2.4 Bayer Revenue in RDC Drugs Business (2020-2025)
11.2.5 Bayer Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca RDC Drugs Introduction
11.3.4 AstraZeneca Revenue in RDC Drugs Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Details
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly RDC Drugs Introduction
11.4.4 Eli Lilly Revenue in RDC Drugs Business (2020-2025)
11.4.5 Eli Lilly Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb RDC Drugs Introduction
11.5.4 Bristol-Myers Squibb Revenue in RDC Drugs Business (2020-2025)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson RDC Drugs Introduction
11.6.4 Johnson & Johnson Revenue in RDC Drugs Business (2020-2025)
11.6.5 Johnson & Johnson Recent Development
11.7 Grand Pharmaceutical Group
11.7.1 Grand Pharmaceutical Group Company Details
11.7.2 Grand Pharmaceutical Group Business Overview
11.7.3 Grand Pharmaceutical Group RDC Drugs Introduction
11.7.4 Grand Pharmaceutical Group Revenue in RDC Drugs Business (2020-2025)
11.7.5 Grand Pharmaceutical Group Recent Development
11.8 China Isotope & Radiation Corporation
11.8.1 China Isotope & Radiation Corporation Company Details
11.8.2 China Isotope & Radiation Corporation Business Overview
11.8.3 China Isotope & Radiation Corporation RDC Drugs Introduction
11.8.4 China Isotope & Radiation Corporation Revenue in RDC Drugs Business (2020-2025)
11.8.5 China Isotope & Radiation Corporation Recent Development
11.9 Dongcheng Pharmaceutical
11.9.1 Dongcheng Pharmaceutical Company Details
11.9.2 Dongcheng Pharmaceutical Business Overview
11.9.3 Dongcheng Pharmaceutical RDC Drugs Introduction
11.9.4 Dongcheng Pharmaceutical Revenue in RDC Drugs Business (2020-2025)
11.9.5 Dongcheng Pharmaceutical Recent Development
11.10 Hengrui Medicine
11.10.1 Hengrui Medicine Company Details
11.10.2 Hengrui Medicine Business Overview
11.10.3 Hengrui Medicine RDC Drugs Introduction
11.10.4 Hengrui Medicine Revenue in RDC Drugs Business (2020-2025)
11.10.5 Hengrui Medicine Recent Development
11.11 Xiantong Pharmaceutical
11.11.1 Xiantong Pharmaceutical Company Details
11.11.2 Xiantong Pharmaceutical Business Overview
11.11.3 Xiantong Pharmaceutical RDC Drugs Introduction
11.11.4 Xiantong Pharmaceutical Revenue in RDC Drugs Business (2020-2025)
11.11.5 Xiantong Pharmaceutical Recent Development
11.12 Bivision
11.12.1 Bivision Company Details
11.12.2 Bivision Business Overview
11.12.3 Bivision RDC Drugs Introduction
11.12.4 Bivision Revenue in RDC Drugs Business (2020-2025)
11.12.5 Bivision Recent Development
11.13 SmartNuclide
11.13.1 SmartNuclide Company Details
11.13.2 SmartNuclide Business Overview
11.13.3 SmartNuclide RDC Drugs Introduction
11.13.4 SmartNuclide Revenue in RDC Drugs Business (2020-2025)
11.13.5 SmartNuclide Recent Development
11.14 Full-Life Technologies
11.14.1 Full-Life Technologies Company Details
11.14.2 Full-Life Technologies Business Overview
11.14.3 Full-Life Technologies RDC Drugs Introduction
11.14.4 Full-Life Technologies Revenue in RDC Drugs Business (2020-2025)
11.14.5 Full-Life Technologies Recent Development
11.15 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
11.15.1 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Details
11.15.2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview
11.15.3 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Introduction
11.15.4 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Revenue in RDC Drugs Business (2020-2025)
11.15.5 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Development
11.16 Nuoyu Pharmaceutical
11.16.1 Nuoyu Pharmaceutical Company Details
11.16.2 Nuoyu Pharmaceutical Business Overview
11.16.3 Nuoyu Pharmaceutical RDC Drugs Introduction
11.16.4 Nuoyu Pharmaceutical Revenue in RDC Drugs Business (2020-2025)
11.16.5 Nuoyu Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global RDC Drugs Market Size Growth Rate by Target Ligand Types (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Antibody-Drug Conjugates (ARC)
Table 3. Key Players of Peptide-Drug Conjugates (PRC)
Table 4. Key Players of Small Molecule-Drug Conjugates (SMRC)
Table 5. Global RDC Drugs Market Size Growth Rate by Medical Uses (US$ Million): 2020 VS 2024 VS 2031
Table 6. Key Players of Diagnostic RDCs
Table 7. Key Players of Therapeutic RDCs
Table 8. Global RDC Drugs Market Size Growth Rate by Therapeutic Radionuclide Properties (US$ Million): 2020 VS 2024 VS 2031
Table 9. Key Players of β-Nuclear Therapy
Table 10. Key Players of α-Nuclear Therapy
Table 11. Global RDC Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 12. Global RDC Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 13. Global RDC Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 14. Global RDC Drugs Market Share by Region (2020-2025)
Table 15. Global RDC Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 16. Global RDC Drugs Market Share by Region (2026-2031)
Table 17. RDC Drugs Market Trends
Table 18. RDC Drugs Market Drivers
Table 19. RDC Drugs Market Challenges
Table 20. RDC Drugs Market Restraints
Table 21. Global RDC Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 22. Global RDC Drugs Market Share by Players (2020-2025)
Table 23. Global Top RDC Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RDC Drugs as of 2024)
Table 24. Ranking of Global Top RDC Drugs Companies by Revenue (US$ Million) in 2024
Table 25. Global 5 Largest Players Market Share by RDC Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 26. Global Key Players of RDC Drugs, Headquarters and Area Served
Table 27. Global Key Players of RDC Drugs, Product and Application
Table 28. Global Key Players of RDC Drugs, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global RDC Drugs Market Size by Target Ligand Types (2020-2025) & (US$ Million)
Table 31. Global RDC Drugs Revenue Market Share by Target Ligand Types (2020-2025)
Table 32. Global RDC Drugs Forecasted Market Size by Target Ligand Types (2026-2031) & (US$ Million)
Table 33. Global RDC Drugs Revenue Market Share by Target Ligand Types (2026-2031)
Table 34. Global RDC Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 35. Global RDC Drugs Revenue Market Share by Application (2020-2025)
Table 36. Global RDC Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 37. Global RDC Drugs Revenue Market Share by Application (2026-2031)
Table 38. North America RDC Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. North America RDC Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 40. North America RDC Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 41. Europe RDC Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Europe RDC Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 43. Europe RDC Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 44. Asia-Pacific RDC Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 45. Asia-Pacific RDC Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 46. Asia-Pacific RDC Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 47. Latin America RDC Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Latin America RDC Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 49. Latin America RDC Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 50. Middle East & Africa RDC Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 51. Middle East & Africa RDC Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 52. Middle East & Africa RDC Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 53. Novartis Company Details
Table 54. Novartis Business Overview
Table 55. Novartis RDC Drugs Product
Table 56. Novartis Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 57. Novartis Recent Development
Table 58. Bayer Company Details
Table 59. Bayer Business Overview
Table 60. Bayer RDC Drugs Product
Table 61. Bayer Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 62. Bayer Recent Development
Table 63. AstraZeneca Company Details
Table 64. AstraZeneca Business Overview
Table 65. AstraZeneca RDC Drugs Product
Table 66. AstraZeneca Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 67. AstraZeneca Recent Development
Table 68. Eli Lilly Company Details
Table 69. Eli Lilly Business Overview
Table 70. Eli Lilly RDC Drugs Product
Table 71. Eli Lilly Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 72. Eli Lilly Recent Development
Table 73. Bristol-Myers Squibb Company Details
Table 74. Bristol-Myers Squibb Business Overview
Table 75. Bristol-Myers Squibb RDC Drugs Product
Table 76. Bristol-Myers Squibb Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 77. Bristol-Myers Squibb Recent Development
Table 78. Johnson & Johnson Company Details
Table 79. Johnson & Johnson Business Overview
Table 80. Johnson & Johnson RDC Drugs Product
Table 81. Johnson & Johnson Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 82. Johnson & Johnson Recent Development
Table 83. Grand Pharmaceutical Group Company Details
Table 84. Grand Pharmaceutical Group Business Overview
Table 85. Grand Pharmaceutical Group RDC Drugs Product
Table 86. Grand Pharmaceutical Group Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 87. Grand Pharmaceutical Group Recent Development
Table 88. China Isotope & Radiation Corporation Company Details
Table 89. China Isotope & Radiation Corporation Business Overview
Table 90. China Isotope & Radiation Corporation RDC Drugs Product
Table 91. China Isotope & Radiation Corporation Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 92. China Isotope & Radiation Corporation Recent Development
Table 93. Dongcheng Pharmaceutical Company Details
Table 94. Dongcheng Pharmaceutical Business Overview
Table 95. Dongcheng Pharmaceutical RDC Drugs Product
Table 96. Dongcheng Pharmaceutical Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 97. Dongcheng Pharmaceutical Recent Development
Table 98. Hengrui Medicine Company Details
Table 99. Hengrui Medicine Business Overview
Table 100. Hengrui Medicine RDC Drugs Product
Table 101. Hengrui Medicine Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 102. Hengrui Medicine Recent Development
Table 103. Xiantong Pharmaceutical Company Details
Table 104. Xiantong Pharmaceutical Business Overview
Table 105. Xiantong Pharmaceutical RDC Drugs Product
Table 106. Xiantong Pharmaceutical Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 107. Xiantong Pharmaceutical Recent Development
Table 108. Bivision Company Details
Table 109. Bivision Business Overview
Table 110. Bivision RDC Drugs Product
Table 111. Bivision Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 112. Bivision Recent Development
Table 113. SmartNuclide Company Details
Table 114. SmartNuclide Business Overview
Table 115. SmartNuclide RDC Drugs Product
Table 116. SmartNuclide Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 117. SmartNuclide Recent Development
Table 118. Full-Life Technologies Company Details
Table 119. Full-Life Technologies Business Overview
Table 120. Full-Life Technologies RDC Drugs Product
Table 121. Full-Life Technologies Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 122. Full-Life Technologies Recent Development
Table 123. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Details
Table 124. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview
Table 125. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Product
Table 126. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 127. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Development
Table 128. Nuoyu Pharmaceutical Company Details
Table 129. Nuoyu Pharmaceutical Business Overview
Table 130. Nuoyu Pharmaceutical RDC Drugs Product
Table 131. Nuoyu Pharmaceutical Revenue in RDC Drugs Business (2020-2025) & (US$ Million)
Table 132. Nuoyu Pharmaceutical Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. RDC Drugs Picture
Figure 2. Global RDC Drugs Market Size Comparison by Target Ligand Types (2020-2031) & (US$ Million)
Figure 3. Global RDC Drugs Market Share by Target Ligand Types: 2024 VS 2031
Figure 4. Antibody-Drug Conjugates (ARC) Features
Figure 5. Peptide-Drug Conjugates (PRC) Features
Figure 6. Small Molecule-Drug Conjugates (SMRC) Features
Figure 7. Global RDC Drugs Market Size Comparison by Medical Uses (2020-2031) & (US$ Million)
Figure 8. Diagnostic RDCs Features
Figure 9. Therapeutic RDCs Features
Figure 10. Global RDC Drugs Market Size Comparison by Therapeutic Radionuclide Properties (2020-2031) & (US$ Million)
Figure 11. β-Nuclear Therapy Features
Figure 12. α-Nuclear Therapy Features
Figure 13. Global RDC Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 14. Global RDC Drugs Market Share by Application: 2024 VS 2031
Figure 15. Prostate Cancer Case Studies
Figure 16. Neuroendocrine Tumors Case Studies
Figure 17. Liver Cancer Case Studies
Figure 18. Kidney Cancer Case Studies
Figure 19. Bone Metastases Case Studies
Figure 20. Others Case Studies
Figure 21. RDC Drugs Report Years Considered
Figure 22. Global RDC Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 23. Global RDC Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 24. Global RDC Drugs Market Share by Region: 2024 VS 2031
Figure 25. Global RDC Drugs Market Share by Players in 2024
Figure 26. Global RDC Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. The Top 10 and 5 Players Market Share by RDC Drugs Revenue in 2024
Figure 28. North America RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. North America RDC Drugs Market Share by Country (2020-2031)
Figure 30. United States RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Canada RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Europe RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Europe RDC Drugs Market Share by Country (2020-2031)
Figure 34. Germany RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. France RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. U.K. RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Italy RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Russia RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Ireland RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific RDC Drugs Market Share by Region (2020-2031)
Figure 42. China RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Japan RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. South Korea RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Southeast Asia RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. India RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Australia & New Zealand RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Latin America RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Latin America RDC Drugs Market Share by Country (2020-2031)
Figure 50. Mexico RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Brazil RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Middle East & Africa RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Middle East & Africa RDC Drugs Market Share by Country (2020-2031)
Figure 54. Israel RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. UAE RDC Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Novartis Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 58. Bayer Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 59. AstraZeneca Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 60. Eli Lilly Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 62. Johnson & Johnson Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 63. Grand Pharmaceutical Group Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 64. China Isotope & Radiation Corporation Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 65. Dongcheng Pharmaceutical Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 66. Hengrui Medicine Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 67. Xiantong Pharmaceutical Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 68. Bivision Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 69. SmartNuclide Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 70. Full-Life Technologies Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 71. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 72. Nuoyu Pharmaceutical Revenue Growth Rate in RDC Drugs Business (2020-2025)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
